Then there's Novavax (NASDAQ:NVAX). The biotech's market cap of $6 billion is minuscule compared to the coronavirus vaccine leaders. But Novavax isn't too far behind the pack: It expects to begin a phase 3 trial of COVID-19 vaccine candidate NVX‑CoV2373 in the U.K. in September, with a U.S. late-stage study kicking off next month.
The reality is that Novavax is keeping up pretty well with the big players in the coronavirus vaccine race. Here's how.